Which up-front therapy combination is best for newly diagnosed multiple myeloma patients? This study is comparing two proteasome inhibitors which are combined with lenalidomide (an iMiD) and dexamethasone (a steroid.) The class of proteasome inhibitors are are critical staple for myeloma therapy, but is one better than another? We are hopeful that this clinical trial can give insight into which proteasome inhibitor is best for which type of patient, age, pre-existing conditions and myeloma genetics. This trial is open in many locations on the East coast including local cancer centers, and will include over 700 newly diagnosed multiple myeloma patients. To learn more about this study or to join, click here: RVD or CRD Clinical Trial for Newly Diagnosed Patients
about the author
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.